Genomic Health Newswire (Page 2)

Genomic Health Newswire (Page 2)

Comprehensive Real-Time News Feed for Genomic Health. (Page 2)

Results 21 - 40 of 486 in Genomic Health

  1. Reference labs face 10% haircut from CMS if proposed fees holdRead the original story w/Photo

    Monday Sep 25 | Seeking Alpha

    ... ince they don't have the scale to absorb the lower rates. It adds that companies with proprietary tests, like Genomic Health ( GHDX +0.6% ), Veracyte ( VCYT -0.7% ), CareDx ( CDNA +3.9% ) and Vermillion ( VRML +4.7% ) should be in good shape.

    Comment?

  2. Liquid Biopsy Market Worth 2.04 Million USD by 2022Read the original story w/Photo

    Monday Sep 25 | PR Newswire

    ... to support research activities in the field of liquid biopsy are aiding market growth in the region. ), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, ...

    Comment?

  3. Genomic Health, Inc. (GHDX) Stake Boosted by Schwab Charles Investment Management Inc.Read the original story w/Photo

    Sunday Sep 24 | IntersportsWire

    Schwab Charles Investment Management Inc. lifted its stake in Genomic Health, Inc. by 3.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 497,340 shares of the medical research company's stock after acquiring an additional 14,665 shares during the quarter.

    Comment?

  4. Head to Head Analysis: Celator PharmaceuticalsRead the original story w/Photo

    Saturday Sep 23 | AmericanBankingNews.com

    Celator Pharmaceuticals and Genomic Health are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. 88.9% of Genomic Health shares are owned by institutional investors.

    Comment?

  5. Insider Selling: Genomic Health, Inc. (GHDX) Insider Sells $155,000.00 in StockRead the original story w/Photo

    Thursday Sep 21 | Daily Political

    Genomic Health, Inc. insider Kimberly J. Popovits sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $31.00, for a total transaction of $155,000.00.

    Comment?

  6. Russell Investments Group Ltd. Lowers Stake in Genomic Health, Inc.Read the original story w/Photo

    Wednesday Sep 20 | Daily Political

    Russell Investments Group Ltd. lowered its stake in shares of Genomic Health, Inc. by 32.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,366 shares of the medical research company's stock after selling 7,956 shares during the quarter.

    Comment?

  7. Genomic Health, Inc. (GHDX) Given Consensus Rating of "Hold" by AnalystsRead the original story w/Photo

    Wednesday Sep 20 | AmericanBankingNews.com

    Shares of Genomic Health, Inc. have earned a consensus rating of "Hold" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and one has assigned a buy recommendation to the company.

    Comment?

  8. Companion Diagnostics Market Report 2016 by Industry Size, Share & Key Drivers 2022Read the original story w/Photo

    Monday Sep 18 | SBWire

    ... market growth are Myriad Genetics, Qiagen, Life Technologies, Abbott, Thermo Fischer Scientific, and Genomic Health. Other players influencing the global market are Roche Holdings, Protagen Diagnostics, Amgen, Agilent Technologies, Myriad Genetics, ...

    Comment?

  9. Genomic Health, Inc. (GHDX) Given Hold Rating at Jefferies Group LLCRead the original story w/Photo

    Sep 15, 2017 | Daily Political

    ... on the company. Cowen and Company restated a hold rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. Zacks Investment Research downgraded Genomic Health from a hold rating to a sell ...

    Comment?

  10. Insider Selling: Genomic Health, Inc. (GHDX) COO Sells 5,000 Shares of StockRead the original story w/Photo

    Sep 14, 2017 | AmericanBankingNews.com

    Genomic Health, Inc. COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total value of $159,300.00.

    Comment?

  11. Genomic Health, Inc. (GHDX) Earns "Hold" Rating from Jefferies Group LLCRead the original story w/Photo

    Sep 14, 2017 | AmericanBankingNews.com

    ... have also issued research reports about the stock. Canaccord Genuity cut their price objective on shares of Genomic Health from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 15th. Cowen and Company ...

    Comment?

  12. Genomic Health and Biocartis Announce Agreement to Develop an Idylla...Read the original story

    Sep 13, 2017 | PressReleasePoint

    Genomic Health , Inc. , the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV , an innovative molecular diagnostics company, today announced an exclusive agreement to develop an in vitro diagnostic version of the Oncotype DX Breast Recurrence ScoreA test on Biocartis' Idyllaa platform that can be performed locally by laboratory partners and in hospitals around the world. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease.

    Comment?

  13. State of Wisconsin Investment Board Buys New Holdings in Genomic Health, Inc.Read the original story w/Photo

    Sep 13, 2017 | IntersportsWire

    State of Wisconsin Investment Board bought a new stake in Genomic Health, Inc. in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 15,000 shares of the medical research company's stock, valued at approximately $488,000.

    Comment?

  14. Genomic Health and Biocartis Announce Agreement to Develop an Idyllaa ...Read the original story

    Sep 12, 2017 | Customer Interaction Solutions

    /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced an exclusive ...

    Comment?

  15. K. Angela Macfarlane Announced as Recipient of Third Annual Ferolyn Powell Leadership AwardRead the original story

    Sep 12, 2017 | Customer Interaction Solutions

    ... as the Stanford Byers Center for Biodesign. Kimberly Popovits, chairman of the Board, CEO and president of Genomic Health, was the recipient of the 2016 Ferolyn Powell Leadership Award. MedtechWomen is a 510(c)(3) educational nonprofit organization ...

    Comment?

  16. Genomic Health Release: New Analysis From German Study Group...Read the original story

    Sep 11, 2017 | BioSpace

    Genomic Health Release: New Analysis From German Study Group Prospective Trial Shows Minimal Distant Recurrence In Patients With Clinically High-Risk Breast Cancer And Low Oncotype DX Breast Recurrence ScoreA Results Following Five Years Of Hormone Therapy Alone Additional large population-based study indicates not all young women under 40 years with node negative breast cancer have aggressive disease-excellent survival without chemotherapy reported at five years for patients with low Recurrence ScoreA results "The results presented at ESMO once again highlight the unique value of Oncotype DXA in providing critical information to personalize and improve the quality of treatment decisions in early breast cancer," said Calvin Chao, Vice President of Global Medical Affairs at Genomic Health.

    Comment?

  17. American Century Companies Inc. Boosts Holdings in Genomic Health, Inc.Read the original story w/Photo

    Sep 11, 2017 | IntersportsWire

    American Century Companies Inc. raised its stake in Genomic Health, Inc. by 0.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 127,294 shares of the medical research company's stock after buying an additional 1,092 shares during the period.

    Comment?

  18. By the End of 2026 Liquid Biopsy Market to Achieve US$ 2,893.7 MnRead the original story w/Photo

    Sep 6, 2017 | SBWire

    ... Some of the key players in the global liquid biopsy market include Genomic Health, Inc., Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation. A majority of key ...

    Comment?

  19. Genomic Health, Inc. (GHDX) Given "Hold" Rating at Cowen and CompanyRead the original story w/Photo

    Sep 4, 2017 | AmericanBankingNews.com

    ... GHDX has been the topic of several other research reports. Zacks Investment Research downgraded shares of Genomic Health from a "hold" rating to a "sell" rating in a research report on Tuesday, August 1st. Jefferies Group LLC restated a "hold" ...

    Comment?

  20. Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics...Read the original story

    Aug 31, 2017 | PressReleasePoint

    REDWOOD CITY, Calif., Aug. 31, 2017 / / -- Genomic Health, Inc. today announced that the company will present results from four Oncotype DX Breast Recurrence ScoreA test studies at the European Society for Medical Oncology 2017 Congress. The conference takes place September 8-12 at the IFEMA, Feria de Madrid, in Madrid, in partnership with the European Association for Cancer Research .

    Comment?